Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer

Patent metadata

Field	Value
Publication number	US-9512129-B2
Application number	US-201514686856-A
Country	US
Kind code	B2
Filing date	Apr 15, 2015
Priority date	Apr 16, 2014
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

First claim

What is claimed is:

1. A solid form comprising (a) 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one; and (b) a coformer selected from the group consisting of gentisic acid and nicotinamide.

2. The solid form of claim 1 , wherein the coformer is gentisic acid.

3. The solid form of claim 1 , wherein the coformer is nicotinamide.

4. The solid form of claim 1 , which is greater than 80% by weight of a crystal form.

5. The solid form of claim 4 , which is greater than 80% by weight of a cocrystal.

6. The solid form of claim 5 , which is greater than 90% by weight of a cocrystal.

7. The solid form of claim 6 , which is greater than 95% by weight of a crystal form.

8. The solid form of claim 7 , which contains less than 3% by weight of other solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

9. The solid form of claim 8 , further comprising amorphous 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

10. The solid form of claim 9 , which is greater than 99% by weight of a crystal form.

11. A pharmaceutical composition comprising the solid form of claim 1 , and a pharmaceutically acceptable excipient or carrier.

12. The pharmaceutical composition of claim 11 , which is a single unit dosage form.

13. The pharmaceutical composition of claim 12 , which is a tablet.

14. The pharmaceutical composition of claim 12 , which is a capsule.

Assignees

• Signal Pharm Llc

Inventors

• Eckert Jeffrey

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title